Joseph Haas

1 day ago | insights.citeline.com | Joseph Haas

Altimmune’s Phase IIb MASH Data Send Share Price Plungingltimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss. Altimmune's Phase IIb MASH data drew mixed reactions, stock price decline • Source: Shutterstock

1 day ago | insights.citeline.com | Joseph Haas |Sushmita Panda |Alaric DeArment

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFoundPlus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.

3 days ago | insights.citeline.com | Joseph Haas

Biogen’s Spinraza Follow-On May Offer Disease-Modifying PotentialBiogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza. Biogen hopes to move from Phase I to Phase III with SMA candidate • Source: Shutterstock

4 days ago | insights.citeline.com | Joseph Haas

Amgen’s MariTide Data Not The Hit Investors SoughtMariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile. Overall profile for Amgen's MariTide in obesity gets mixed reviews • Source: Shutterstock

5 days ago | insights.citeline.com | Joseph Haas

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention DataHaving recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%. Cidara's Phase IIb flu prevention data tops prophylactic effect typically seen with vaccines • Source: Shutterstock